Literature DB >> 15820257

Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses.

Zeinab Abdel-Wahab1, Robin Cisco, Jens Dannull, Tomio Ueno, Omar Abdel-Wahab, Matthew F Kalady, Mark W Onaitis, Douglas S Tyler, Scott K Pruitt.   

Abstract

BACKGROUND: Cotransfection of dendritic cells (DC) with MART-1 and constitutively active TLR4 (caTLR4) RNA enhances the maturation of DC.
MATERIALS AND METHODS: Immature DC were cotransfected with RNA constructs encoding MART-1 and caTLR4, and CTL responses were analyzed.
RESULTS: Cotransfection of DC with MART-1 + caTLR4 enhanced the expression of CD80 and CD83 surface markers and increased the secretion of cytokines IL-6, IL-12, and TNFalpha. Neither the native nor the A27L-modified MART-1 RNA could induce significant DC maturation or cytokine secretion. More importantly, DC cotransfected with caTLR4 + MART-1 RNA induced MART-1-specific CTL responses of a higher magnitude than DC transfected with either the native or A27L MART-1 RNA. When the MART-1 RNA-transfected DC were treated with DC-maturing cytokines, the induced CTL were less frequent and less lytic than those induced with MART-1 + caTLR4. A 2- to 100-fold increase in MART-1 tetramer+ cells and 2- to 10-fold increases in IFNgamma secretion and cytotoxicity were seen in CTL induced with MART-1 + caTLR4 compared to CTL induced with either MART-1 or A27L RNA. CTL induced with the mixed RNA displayed high percentages of CD8+ cells coexpressing CD45RA, CD56, and 2B4 antigens. Transfection with caTLR4 alone induced DC maturation, but did not induce lytic CTL, suggesting that CTL responses were induced solely by MART-1 epitopes.
CONCLUSIONS: caTLR4 increases the CTL-inducing capacity of DC generating a lytic response specific for the accompanying antigen. These results demonstrate the possibility of enhancing the immunogenicity of the native MART-1 and other RNA derived from weakly immunogenic tumors in DC-based immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820257     DOI: 10.1016/j.jss.2004.10.002

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  11 in total

1.  Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA.

Authors:  Miwako Narita; Nozomi Tochiki; Anri Saitoh; Norihiro Watanabe; Masami Kaji; Noriyuki Satoh; Akie Yamahira; Takeshi Nakamura; Masayoshi Masuko; Tatsuo Furukawa; Ken Toba; Ichiro Fuse; Yoshifusa Aizawa; Masuhiro Takahashi
Journal:  Med Oncol       Date:  2008-12-05       Impact factor: 3.064

2.  mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity.

Authors:  Gal Cafri; Adi Sharbi-Yunger; Esther Tzehoval; Zoya Alteber; Tamar Gross; Ezra Vadai; Alon Margalit; Gideon Gross; Lea Eisenbach
Journal:  Mol Ther       Date:  2015-05-22       Impact factor: 11.454

Review 3.  Current progress of siRNA/shRNA therapeutics in clinical trials.

Authors:  John C Burnett; John J Rossi; Katrin Tiemann
Journal:  Biotechnol J       Date:  2011-07-11       Impact factor: 4.677

Review 4.  RNA vaccines in cancer treatment.

Authors:  Anita Bringmann; Stefanie Andrea Erika Held; Annkristin Heine; Peter Brossart
Journal:  J Biomed Biotechnol       Date:  2010-06-01

Review 5.  Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.

Authors:  Karine Breckpot; David Escors
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2009-12       Impact factor: 2.895

6.  Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.

Authors:  Jens Dannull; N Rebecca Haley; Gary Archer; Smita Nair; David Boczkowski; Mark Harper; Nicole De Rosa; Nancy Pickett; Paul J Mosca; James Burchette; Maria A Selim; Duane A Mitchell; John Sampson; Douglas S Tyler; Scott K Pruitt
Journal:  J Clin Invest       Date:  2013-06-24       Impact factor: 14.808

7.  Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.

Authors:  Minami Iwabuchi; Miwako Narita; Takayoshi Uchiyama; Shunpei Iwaya; Eri Oiwa; Yoshinori Nishizawa; Shigeo Hashimoto; Aude Bonehill; Noriyuki Kasahara; Jun Takizawa; Masuhiro Takahashi
Journal:  Mol Med Rep       Date:  2015-04-24       Impact factor: 2.952

8.  Targeting lentiviral vectors for cancer immunotherapy.

Authors:  Frederick Arce; Karine Breckpot; Mary Collins; David Escors
Journal:  Curr Cancer Ther Rev       Date:  2011-11

9.  Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells.

Authors:  Kira Minkis; Daniel G Kavanagh; Galit Alter; Dusan Bogunovic; David O'Neill; Sylvia Adams; Anna Pavlick; Bruce D Walker; Mark A Brockman; Rajesh T Gandhi; Nina Bhardwaj
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

Review 10.  RNAi-based therapeutics-current status, challenges and prospects.

Authors:  Katrin Tiemann; John J Rossi
Journal:  EMBO Mol Med       Date:  2009-06       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.